Last reviewed · How we verify
NCT00001506
Evaluation and Treatment of Patients With Dermatologic Diseases
trial in Dermatologic Diseases in 453 participants. Completed in 1 April 2025.
26 March 2025
Quick facts
| Lead sponsor | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 453 |
| Start date | 22 August 1996 |
| Primary completion | 26 March 2025 |
| Estimated completion | 1 April 2025 |
| Sites | 1 location across United States |
Conditions studied
- Dermatologic Diseases — all drugs for Dermatologic Diseases →
- Systemic Diseases With Cutaneous Manifestations — all drugs for Systemic Diseases With Cutaneous Manifestations →
Sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Who can join
Adults 1 Day to 120, any sex, with Dermatologic Diseases or Systemic Diseases With Cutaneous Manifestations. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a training, natural history of disease, and screening protocol for the evaluation, treatment and follow-up of patients with dermatologic diseases and systemic diseases with cutaneous manifestations. Patients enrolled in this protocol will be evaluated and treated according to generally available, standard procedures and therapeutic modalities. Samples of blood and skin will be studied by routine and specialized investigative methods to establish these patients' diagnosis, response to treatment, and/or disease progression.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Predicting cancer immunotherapy response from gut microbiomes using machine learning models.
Liang H, Jo JH, Zhang Z, MacGibeny MA, et al · · 2022 · cited 29× · PMID 35875611 · DOI 10.18632/oncotarget.28252
Verify or expand the search:
- PubMed search for NCT00001506
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) trials
Trials by the same sponsor.
- NCT07012057 — Study of Deucravacitinib for Refractory Adults With Dermatomyositis/Juvenile Dermatomyositis · Phase 2 · withdrawn
- NCT06238531 — A Clinical Trial to Evaluate Safety of Gusacitinib in Patients With Systemic Lupus Erythematosus (SLE) or Lupus · Phase 1 · withdrawn
- NCT05440422 — The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN- · Phase 2 · recruiting
- NCT05738824 — Natural History of Inflammatory Muscle Diseases · recruiting
- NCT05567198 — Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in SLE Subjects Receiving Cyclophosphamide as Det · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00001506 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- Last refreshed: 13 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00001506.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing